HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys.

HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys.

A key challenge for the development of a cure to HIV-1 infection is the persistent viral reservoir established during early infection. Previous studies using Toll-like receptor 7 (TLR7) agonists and broadly neutralizing antibodies (bNAbs) have shown delay or prevention of viral rebound following ant...

Full description

Bibliographic Details
Main Authors: Brian Moldt, Abishek Chandrashekar, Erica N Borducchi, Joseph P Nkolola, Heather Stephenson, Mark Nagel, Magdeleine Hung, Joshua Goldsmith, Craig S Pace, Brian Carr, Nathan D Thomsen, Wade S Blair, Romas Geleziunas, Dan H Barouch
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-04-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1010467

Internet

https://doi.org/10.1371/journal.ppat.1010467

Similar Items